19. Jul 2026
Description
(AWP Alliance News) - PolyPeptide Group AG reported H1 2026 revenue of EUR 236.6 million, up 41.6% from the prior-year period, as EBITDA margin widened to 20.7% from 2.7%. Result for the period swung to profit of about EUR 9 million from a loss of EUR 26.5 million a year earlier.
Metabolic therapeutics revenue climbed to EUR 161.7 million, representing about 68% of total revenue, while large pharma customers accounted for about 72%. The group raised its full-year outlook to 25-30% revenue growth versus 2025, targeting a high-teens EBITDA margin.
https://www.publicnow.com/view/2BF5E9841E579D1D401FAAB6B5B9E96053637004…
Disclaimer: This news brief was created using generative artificial intelligence. PolyPeptide Group AG published the original content used to generate this news brief via EQS News on July 20, 2026, and is solely responsible for the information contained therein.
